Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 May;13(5):313-320.
doi: 10.1038/nrrheum.2017.54. Epub 2017 Apr 6.

Fine tuning of immunometabolism for the treatment of rheumatic diseases

Jillian P Rhoads  1 , Amy S Major  2 , Jeffrey C Rathmell  3
Affiliations
Review

Fine tuning of immunometabolism for the treatment of rheumatic diseases

Jillian P Rhoads et al. Nat Rev Rheumatol. 2017 May.

Abstract

All immune cells depend on specific and efficient metabolic pathways to mount an appropriate response. Over the past decade, the field of immunometabolism has expanded our understanding of the various means by which cells modulate metabolism to achieve the effector functions necessary to fight infection or maintain homeostasis. Harnessing these metabolic pathways to manipulate inappropriate immune responses as a therapeutic strategy in cancer and autoimmunity has received increasing scrutiny by the scientific community. Fine tuning immunometabolism to provide the desired response, or prevent a deleterious response, is an attractive alternative to chemotherapy or overt immunosuppression. The various metabolic pathways used by immune cells in rheumatoid arthritis, systemic lupus erythematosus and osteoarthritis offer numerous opportunities for selective targeting of specific immune cell subsets to manipulate cellular metabolism for therapeutic benefit in these rheumatologic diseases.

PubMed Disclaimer

Conflict of interest statement

Competing interests statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1. Metabolic reprogramming of immune cell populations matches immunological function
Naive T cells, resting B cells and macrophages utilize a catabolic and oxidative metabolic programme. After stimulation via antigen receptor with co-stimulation or through pattern-recognition receptors such as Toll-like receptors (TLRs), these immune cells undergo metabolic reprogramming. Effector lymphocytes or inflammatory macrophages induce an anabolic meta bolic programme with highly increased nutrient uptake for glycolysis and glutamine metabolism. Regulatory cells or alternatively activated macrophages, by contrast, primarily utilize a programme of lipid and pyruvate oxidation. These programmes are important to the function of each subset; if the cellular metabolism does not match the cell fate, immune cells will fail to gain appropriate functional capacity. BCR, B cell receptor; CTLA-4, cytotoxic T lymphocyte protein 4; HIF, hypoxia-inducible factor; mTOR, mechanistic target of rapamycin; PD-1, programmed cell death protein 1; PGCla, peroxisome proliferator-activated receptor γ co-activator 1-α; TCR, T cell receptor; Treg cell, regulatory T cell.
Figure 2
Figure 2. Metabolic processes to target in the treatment of rheumatologic diseases
Metabolic areas and key current or potential targets for drugs to modify immunometabolism and shift immune cell subsets and fate are indicated. 2-DG, 2-deoxy-d-glucose; ASCT2, solute carrier family 1 member 5; DCA, dichloroacetate; ETC, electron transport chain; GLUT1, glucose transporter 1; HIF-1α, hypoxia-inducible factor 1α; HK, hexokinase; LDHA, lactate dehydrogenase A; mTORC, mechanistic target of rapamycin complex; PDHK1, pyruvate dehydrogenase kinase 1; PFKFB3. 6-Phosphofructo 2-kinase/fructose-2,6-bisphosphatase 3.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Yildirim-Toruner C, Diamond B. Current and novel therapeutics in the treatment of systemic lupus erythematosus. J. Allergy Clin. Immunol. 2011;127:303–312. - PMC - PubMed
    1. Kahlenberg JM, Fox DA. Advances in the medical treatment of rheumatoid arthritis. Hand Clin. 2011;27:11–20. - PMC - PubMed
    1. Sokolove J, Lepus CM. Role of inflammation in the pathogenesis of osteoarthritis: latest findings and interpretations. Ther. Adv. Musculoskelet. Dis. 2013;5:77–94. - PMC - PubMed
    1. Hirahara K, Schwartz D, Gadina M, Kanno Y, O’Shea JJ. Targeting cytokine signaling in autoimmunity: back to the future and beyond. Curr. Opin. Immunol. 2016;43:89–97. - PubMed
    1. Tanaka Y, Nakayamada S, Okada Y. Osteoblasts and osteoclasts in bone remodeling and inflammation. Curr. Drug Targets Inflamm. Allergy. 2005;4:325–328. - PubMed